{"id":"NCT02020031","sponsor":"Mayo Clinic","briefTitle":"Regional Prophylactic Vancomycin in Revision Total Knee Replacement","officialTitle":"Regional Prophylactic Vancomycin in Revision Total Knee Replacement","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2013-12","primaryCompletion":"2015-06","completion":"2015-06","firstPosted":"2013-12-24","resultsPosted":"2016-11-25","lastUpdate":"2016-11-25"},"enrollment":22,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Arthropathy of Knee Joint"],"interventions":[{"type":"DRUG","name":"Vancomycin","otherNames":["Vancocin"]}],"arms":[{"label":"Vancomycin 500mg intraosseous","type":"EXPERIMENTAL"},{"label":"Vancomycin 1g IV","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine whether or not giving a lower dose of antibiotics (Vancomycin) in the area where it is needed (the knee joint) is more effective at preventing infection than the current standard dose which is given intravenously (IV) through a wrist vein.","primaryOutcome":{"measure":"Mean Concentration of Vancomycin in Subcutaneous Fat","timeFrame":"Baseline to 24 hours","effectByArm":[{"arm":"Vancomycin 500mg Intraosseous","deltaMin":94.1,"sd":69},{"arm":"Vancomycin 1g IV","deltaMin":3.2,"sd":1.8}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":10},"commonTop":["Elevated temperature post surgery","Altered mental state","Hypotension","Intermittent atrial tachycardia","Hyponatremia"]}}